High expression of microRNA-130b correlates with poor prognosis of patients with hepatocellular carcinoma
- PDF / 534,203 Bytes
- 6 Pages / 595.276 x 793.701 pts Page_size
- 51 Downloads / 204 Views
RESEARCH
Open Access
High expression of microRNA-130b correlates with poor prognosis of patients with hepatocellular carcinoma Wen-yao Wang*, Hong-fei Zhang, Lei Wang, Yan-peng Ma, Fei Gao, Shao-jun Zhang and Li-chao Wang
Abstract Background: Whether microRNA-130b(miR-130b) can serve as a prognostic biomarker of hepatocellular carcinoma (HCC) has not been investigated. In the present study, we investigated the feasibility of miR-130b as a novel prognostic biomarker for HCC. Methods: We retrospectively investigated 97 patients diagnosed with HCC who underwent routine curative surgery between May 2007 and July 2012. miR-130b expression in HCC tissues and paired normal adjacent liver tissues was measured by reverse transcription and real-time PCR (RT-PCR). Survival curves were plotted using the Kaplan-Meier method and differences in survival rates were analyzed using the log-rank test. Results: miR-130b expression level was significantly higher in HCC tissues compared with normal adjacent liver tissues (P < 0.0001). The 5-year overall survival (OS) of high miR-130b expression group was significantly shorter than that of low miR-130b expression group (43.6% vs. 71.5%; P = 0.022). Moreover, the 5-year disease-free survival (DFS) of high miR-130b expression group was also significantly shorter than that of low miR-130b expression group (25.9% vs. 63.9%; P = 0.012). In a multivariate Cox model, we found that miR-130b expression was an independent prognostic factor for both 5-year OS (hazards ratio [HR] = 2.523, 95% confidence interval [CI] = 1.024-7.901, P = 0.011) and 5-year DFS (HR = 4.003, CI = 1.578-7.899, P = 0.005) in HCC. Conclusion: The results indicated that high expression of microRNA-130b was correlated with significant characteristics of patients with HCC, and it might be useful as a novel prognostic biomarker for HCC. Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/ 13000_2014_160
Background Hepatocellular carcinoma (HCC) is the third most common cause of mortality from cancer worldwide [1]. In China, HCC is the second highest cancer killer since the 1990s, which alone accounts for 53% of all liver cancer deaths worldwide [2]. More than 90% of HCC cases develop in chronically inflamed liver as a result of viral hepatitis, alcohol abuse and in increasing incidence in patients with non-alcoholic fatty liver disease [3]. Although the clinical staging systems for HCC have been used in routine clinical decision making, there is still a need to refine and complement outcome predictions. Modifications of these * Correspondence: [email protected] Department of General Surgery, The Second Hospital of hebei Medical university, Shijiazhuang, Hebei 050000, China
staging systems by the addition of new biomarkers are likely to improve the prognostic assessment of HCC patients and could therefore fulfill a clinical need [4-9]. MicroRNAs (miRNAs) are endogenously expressed, small interfering RNAs [10]. They are transcribed as precursor molecul
Data Loading...
